CS Pharmaceuticals Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

CS Pharmaceuticals General Information

Description

Developer of ophthalmology and rare disease pharmaceuticals designed to address unmet medical needs in specialty therapeutic areas. The company focuses on discovering, in-licensing, and developing drug candidates that target the underlying pathophysiology of meibomian gland dysfunction and associated dry eye disease, with activities spanning molecule selection, preclinical evaluation, clinical trial design, and regulatory preparation, enabling ophthalmology specialists and healthcare providers to access new treatment options that address unmet clinical needs in ocular surface care.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 167-169 Great Portland Street 5th Floor
  • London W1W 5PF
  • England, United Kingdom
+44 020
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 167-169 Great Portland Street 5th Floor
  • London W1W 5PF
  • England, United Kingdom
+44 020

CS Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CS Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Clinical Trials - Phase 3
3. Later Stage VC 31-Dec-2025 Completed Generating Revenue
2. Early Stage VC 25-Mar-2024 $4.12M $9.1M Completed Clinical Trials - Phase 3
1. Early Stage VC 16-Nov-2021 $4.96M $4.96M Completed Clinical Trials - Phase 3
To view CS Pharmaceuticals’s complete valuation and funding history, request access »

CS Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 853,809 $0.000001 $1.03 $1.03 1x $1.03 4.51%
Ordinary 4,257,151 $0.000001 $0.94 $0.94 1x $0.94 22.5%
To view CS Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CS Pharmaceuticals Patents

CS Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190151334-A1 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular suface Active 21-Nov-2017
AU-2018372185-A1 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Active 21-Nov-2017
AU-2018372185-B2 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Active 21-Nov-2017
EP-3713544-A2 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Pending 21-Nov-2017
US-11759472-B2 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Active 21-Nov-2017 A61K31/573
To view CS Pharmaceuticals’s complete patent history, request access »

CS Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CS Pharmaceuticals Acquisitions (1)

CS Pharmaceuticals’s most recent deal was a Merger/Acquisition with AxeroVision. The deal was made on 28-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AxeroVision 28-Jul-2023 Merger/Acquisition Drug Discovery
To view CS Pharmaceuticals’s complete acquisitions history, request access »

CS Pharmaceuticals FAQs

  • When was CS Pharmaceuticals founded?

    CS Pharmaceuticals was founded in 2020.

  • Where is CS Pharmaceuticals headquartered?

    CS Pharmaceuticals is headquartered in London, United Kingdom.

  • What is the size of CS Pharmaceuticals?

    CS Pharmaceuticals has 7 total employees.

  • What industry is CS Pharmaceuticals in?

    CS Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is CS Pharmaceuticals a private or public company?

    CS Pharmaceuticals is a Private company.

  • What is CS Pharmaceuticals’s current revenue?

    The current revenue for CS Pharmaceuticals is .

  • How much funding has CS Pharmaceuticals raised over time?

    CS Pharmaceuticals has raised $11.9M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process